Ph3 study of (Dato-DXd) with (AZD2936) NSCLC with actionable genomic alterations (TROPION-LUNG10)
Phase III Clinical Trial
A Phase III Randomised Open-label Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC greater than or equal to 50%) and Without Actionable Genomic Alterations (TROPION-Lung10) (D7632C00001)